Switch theme
Sign up to access all valuation multiples
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
1999
818
LTM Revenue $173M
LTM EBITDA -$81.6M
$176M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Standard BioTools has a last 12-month revenue of $173M and a last 12-month EBITDA of -$81.6M.
In the most recent fiscal year, Standard BioTools achieved revenue of $174M and an EBITDA of -$118M.
Standard BioTools expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Standard BioTools valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $106M | $174M | XXX | XXX | XXX |
| Gross Profit | $37.1M | $50.5M | XXX | XXX | XXX |
| Gross Margin | 35% | 29% | XXX | XXX | XXX |
| EBITDA | -$54.5M | -$118M | XXX | XXX | XXX |
| EBITDA Margin | -51% | -68% | XXX | XXX | XXX |
| Net Profit | -$190M | -$74.7M | XXX | XXX | XXX |
| Net Margin | -179% | -43% | XXX | XXX | XXX |
| Net Debt | n/a | $11.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Standard BioTools's stock price is $1.
Standard BioTools has current market cap of $436M, and EV of $176M.
See Standard BioTools trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $176M | $436M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Standard BioTools has market cap of $436M and EV of $176M.
Standard BioTools's trades at 1.0x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate Standard BioTools's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Standard BioTools and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $176M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | XXX | XXX |
| P/E | -3.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStandard BioTools's NTM/LTM revenue growth is 1%
Standard BioTools's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Standard BioTools's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Standard BioTools's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Standard BioTools and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 64% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -68% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 117% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -67% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 126% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Standard BioTools acquired XXX companies to date.
Last acquisition by Standard BioTools was XXXXXXXX, XXXXX XXXXX XXXXXX . Standard BioTools acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Standard BioTools founded? | Standard BioTools was founded in 1999. |
| Where is Standard BioTools headquartered? | Standard BioTools is headquartered in United States of America. |
| How many employees does Standard BioTools have? | As of today, Standard BioTools has 818 employees. |
| Who is the CEO of Standard BioTools? | Standard BioTools's CEO is Dr. Michael Egholm, PhD. |
| Is Standard BioTools publicy listed? | Yes, Standard BioTools is a public company listed on NAS. |
| What is the stock symbol of Standard BioTools? | Standard BioTools trades under LAB ticker. |
| When did Standard BioTools go public? | Standard BioTools went public in 2011. |
| Who are competitors of Standard BioTools? | Similar companies to Standard BioTools include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Standard BioTools? | Standard BioTools's current market cap is $436M |
| What is the current revenue of Standard BioTools? | Standard BioTools's last 12-month revenue is $173M. |
| What is the current EBITDA of Standard BioTools? | Standard BioTools's last 12-month EBITDA is -$81.6M. |
| What is the current EV/Revenue multiple of Standard BioTools? | Current revenue multiple of Standard BioTools is 1.0x. |
| What is the current EV/EBITDA multiple of Standard BioTools? | Current EBITDA multiple of Standard BioTools is -2.2x. |
| What is the current revenue growth of Standard BioTools? | Standard BioTools revenue growth between 2023 and 2024 was 64%. |
| Is Standard BioTools profitable? | Yes, Standard BioTools is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
